SK

Suzanne Kayne

North America, California, United States, Los Angeles

Description

Suzanne Kayne

Investor Profile

Suzanne Kayne has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Pharmaceutical, Therapeutics.

Stage Focus

  • Series B (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Suzanne Kayne frequently co-invest with?

Ditch Plains Capital Management LP
North America, New York, United States, Manhasset
Co-Investments: 1
Avidity Partners
North America, Texas, United States, Dallas
Co-Investments: 1
RTW Investments
North America, New York, United States, New York
Co-Investments: 1
Franklin Templeton
North America, California, United States, San Mateo
Co-Investments: 1
LV
North America, New York, United States, New York
Co-Investments: 1
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 1
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 1
Highline Capital Management
North America, New York, United States, New York
Co-Investments: 1
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 1
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 1

Which angels does Suzanne Kayne often collaborate with?

RK
North America, California, United States, Los Angeles
Shared Deals: 1

What are some of recent deals done by Suzanne Kayne?

Athira Pharma

Seattle, Washington, United States

Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.

BiotechnologyPharmaceuticalTherapeutics
Series BJun 4, 2020
Amount Raised: $85,000,000